{
 "awd_id": "0349884",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "SBIR Phase II:   Scalable Synthesis and Processing of Nanocrystalline Hydroxyapatite",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "Gregory T. Baxter",
 "awd_eff_date": "2004-02-15",
 "awd_exp_date": "2008-01-31",
 "tot_intn_awd_amt": 499999.0,
 "awd_amount": 999998.0,
 "awd_min_amd_letter_date": "2004-02-05",
 "awd_max_amd_letter_date": "2005-08-30",
 "awd_abstract_narration": "0349884\r\nAhn\r\n\r\nThis Small Business Innovation Research Phase II Project proposes to use  a  newly developed synthetic nanocrystalline hydroxyapatite (HAP) bone material to produce high-strength, resorbable synthetic bone implants for anterior cruciate ligament surgeries. This material solves the problem of current orthopedic implants (made of polymer and/or metal) which either permanently reside as foreign material in the body or quickly degrade into  a  formless  mass  of  non-ossified,  non-load  bearing  tissue.    The  objectives  of  the Phase II work are  to concurrently  scale up  manufacturing processes for HAP to  near-commercial levels  while developing an anterior cruciate ligament  (ACL)  prototype  product  for testing  in  vivo.\r\n\r\nThe commercial impact of this project will be in the area of orthopedics. The proposed technology will help decrease the time of healing in surgeries requiring implants (fractiures, ACL) and will minimize the need for second surgeries to remove the screws and/or to correct for morbidities.\r\n",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Edward",
   "pi_last_name": "Ahn",
   "pi_mid_init": "S",
   "pi_sufx_name": "",
   "pi_full_name": "Edward S Ahn",
   "pi_email_addr": "eahn@angstrommedica.com",
   "nsf_id": "000486734",
   "pi_start_date": "2004-02-05",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Angstrom Medica, Incorporated",
  "inst_street_address": "150 -A New Boston Street",
  "inst_street_address_2": "",
  "inst_city_name": "Woburn",
  "inst_state_code": "MA",
  "inst_state_name": "Massachusetts",
  "inst_phone_num": "7819336121",
  "inst_zip_code": "018010000",
  "inst_country_name": "United States",
  "cong_dist_code": "05",
  "st_cong_dist_code": "MA05",
  "org_lgl_bus_name": null,
  "org_prnt_uei_num": null,
  "org_uei_num": null
 },
 "perf_inst": {
  "perf_inst_name": "Angstrom Medica, Incorporated",
  "perf_str_addr": "150 -A New Boston Street",
  "perf_city_name": "Woburn",
  "perf_st_code": "MA",
  "perf_st_name": "Massachusetts",
  "perf_zip_code": "018010000",
  "perf_ctry_code": "US",
  "perf_cong_dist": "05",
  "perf_st_cong_dist": "MA05",
  "perf_ctry_name": "",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "159100",
   "pgm_ele_name": "STTR Phase II"
  },
  {
   "pgm_ele_code": "537300",
   "pgm_ele_name": "SBIR Phase II"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "1788",
   "pgm_ref_txt": "Nanomanufacturing"
  },
  {
   "pgm_ref_code": "9163",
   "pgm_ref_txt": "SINGLE DIVISION/UNIVERSITY - INDUSTRY"
  },
  {
   "pgm_ref_code": "AMPP",
   "pgm_ref_txt": "ADVANCED MATERIALS & PROCESSING PROGRAM"
  }
 ],
 "app_fund": [
  {
   "app_code": "0104",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "490100",
   "fund_code": "app-0104",
   "fund_name": "",
   "fund_symb_id": ""
  },
  {
   "app_code": "0105",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "490100",
   "fund_code": "app-0105",
   "fund_name": "",
   "fund_symb_id": ""
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2004,
   "fund_oblg_amt": 499999.0
  },
  {
   "fund_oblg_fiscal_yr": 2005,
   "fund_oblg_amt": 499999.0
  }
 ],
 "por": null
}